Journal of Neuroinfectious Diseases
Open Access

Infections that alter the brain’s structure are known as neuroinfectious disorders. We provide unmatched treatment for a variety of neuro-infectious disorders at Mount Sinai Health System, including meningitis, neuro-AIDS, and neuro-HIV. Our properly educated personnel and highly qualified neurologists have years of expertise treating these difficult illnesses. Any neurologic disorder brought on by an HIV infection is referred to as neuroAIDS. Patients with neurological illnesses including dementia, neuropathy, brain infections, and problems with the spinal cord and muscles who are HIV-positive can get compassionate, all encompassing treatment from the Mount Sinai NeuroAIDS Programme. Our experts continue to conduct research and offer education with the aim of improving the day-to-day lives of patients afflicted by these disorders [1-3]. They have made important contributions to the area of NeuroAIDS.

Clinicians have a unique challenge when treating infectious disorders of the nervous system since these conditions are generally uncommon, frequently severe enough to result in harm or death, and frequently curable. Neuroinfectious disease-causing organisms have an innate tendency to grow swiftly. Similar to how understanding of these illnesses will grow and change significantly during a clinician’s career [4]. Neurologists must always stay up to speed on neuroinfectious illness in order to provide patients with the best care. Since infections may take many different forms, it can be challenging for physicians to rule them out when figuring out what is causing a patient’s complaint. For a precise diagnosis and treatment plan to be developed, quick identification of the causing organism is essential. Although cultivating the species is still common for bacterial diseases, quicker identification is frequently required. Immune response may aid in the diagnosis of various illnesses, such as syphilis, and antigen identification is crucial in the rapid diagnosis of some fungal infections, such as Cryptococcus. The challenges of making an etiologic diagnosis of viral disease have been greatly lessened by the expanding availability of PCR testing [5,6]. The introduction of HIV has brought attention to how quickly neuroID is evolving as a field, inspiring the creation of the neuroHIV special emphasis. Over 30 million individuals are now affected by this illness, which was unknown when any of us were in training. It has been related to a variety of main neurologic issues as well as noticeably increased chances of formerly uncommon opportunistic conditions. It is not a universally applicable foe, but rather has evolved into geographically and genetically diverse subtypes. The prognosis for HIV-positive individuals has improved with the fast improvement of medicines, but the brain is a safe sanctuary where it might emerge even when typical systemic illness indicators appear to be comforting [7]. Acute HIV infection and the virus’s escape from long-term control through therapy (Hoogland and Portegies) are two new areas of HIV knowledge that are covered in this issue’s papers, which educate doctors.

All neurologists should make an investment in lifetime learning on emerging infectious disease challenges since they have an impact on the neurological system. The work of a group of experts devoted to this topic has to be supported by our nation’s research organisation as well. These neurologic illnesses, which are damaging yet curable, must be ignored any longer. Poor outcomes are likely to occur if patients are treated by physicians who lack training in neurologic diagnosis and management [8]. Fortunately, the AAN and modern communications have enabled professionals from all over the world to connect with those who possess particular expertise. We must, however, continue to rely on a core group of professionals with in-depth knowledge of both infectious illness research and clinical expertise in its neurological manifestations. Modern tools with molecular pathways and the capability of new imaging techniques provide interesting employment options for people interested in investigating neuroID. There are just a few big university departments that teach NeuroID, and there is no set evaluation procedure. To fund the expenditures of formal testing necessary by approved fellowship courses, there haven’t been enough trainees [9,10]. On the other hand, current experts often mentor trainees working in this area and frequently provide a multi-year clinical and research fellowship that jumpstarts the trainee’s academic career. Training frequently includes a focus on neuroimmunology and neuroID, a logical and beneficial career combination that expands practise prospects to encompass prevalent neurologic diseases like multiple sclerosis.

Conclusion

Alternative career paths have been explored, including as professions in global health, neurologic intensive care training, and hospitalist training combined. These neuroID experts are intended to lead investigations to better understand the pathophysiology that leads to the disorders, help teach doctors throughout the world about these illnesses, and conserve and create diagnostic and treatment tools that may one day save lives. We encourage neurologists to become members of the AAN’s NeuroID Section, where those in need of more training may get it from the Section’s leaders.

Acknowledgement

Not applicable.

Conflict of Interest

Author declares no conflict of interest.

1. Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ (2006) Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 19:259-282.

Indexed at, Google Scholar, Crossref

2. Pijper A, Pullinger BD (1927) South African nocardiases. J Trop Med Hyg 32:153-156.

Google Scholar

3. Wilson RW, Steingrube VA, Brown BA, Blacklock Z, Jost KC, et al. (1997) Recognition of a Nocardia transvalensis complex by resistance to aminoglycosides, including amikacin, and PCR-restriction fragment length polymorphism analysis. J Clin Microbiol 35:2235-2242.

Indexed at, Google Scholar, Crossref

4. Conville PS, Brown JM, Steigerwalt AG, Brown-Elliott BA, Witebsky FG (2008) Nocardia wallacei sp. nov. and Nocardia blacklockiae sp. nov., human pathogens and members of the “Nocardia transvalensis Complex”. J Clin Microbiol 46:1178-1184.

Indexed at, Google Scholar, Crossref

5. Conville PS, Brown-Elliott BA, Wallace RJ, Witebsky FG, Koziol D, et al. (2012) Multisite reproducibility of the broth microdilution method for susceptibility testing of Nocardia species. J Clin Microbiol 50:1270-1280.

Indexed at, Google Scholar, Crossref

6. Uhde KB, Pathak S, McCullum I, Jannat-Khah DP, Shadomy SV, et al. (2010) Antimicrobial-resistant nocardia isolates, United States, 1995–2004. Clin Infect Dis 51:1445-1448.

Indexed at, Google Scholar, Crossref

7. Larruskain J, Idigoras P, Marimón JM, Pérez-Trallero E (2011) Susceptibility of 186 Nocardia sp. isolates to 20 antimicrobial agents. Antimicrob Agents Chemother 55:2995-2998.

Indexed at, Google Scholar, Crossref

8. Tremblay J, Thibert L, Alarie I, Valiquette L, Pépin J (2011) Nocardiosis in Quebec, Canada, 1988–2008. Clin Microbiol Infect 17:690-696.

Indexed at, Google Scholar, Crossref

9. Drancourt M, Berger P, Raoult D (2004) Systematic 16S rRNA gene sequencing of atypical clinical isolates identified 27 new bacterial species associated with humans. J Clin Microbiol 42:2197-2202.

Indexed at, Google Scholar, Crossref

10. Yorke RF, Rouah E (2003) Nocardiosis with brain abscess due to an unusual species, Nocardia transvalensis. Arch Pathol Lab Med 127:224-226.

Indexed at, Google Scholar, Crossref